An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Orlistat | Orlistat can cause a decrease in the absorption of Alitretinoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | Alitretinoin may increase the hepatotoxic activities of Methotrexate. |
| Diethylstilbestrol | The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Alitretinoin. |
| Estradiol | The therapeutic efficacy of Estradiol can be decreased when used in combination with Alitretinoin. |
| Ethinylestradiol | The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Alitretinoin. |
| Mestranol | The therapeutic efficacy of Mestranol can be decreased when used in combination with Alitretinoin. |
| Estradiol cypionate | The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Alitretinoin. |
| Estradiol valerate | The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Alitretinoin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Alitretinoin. |
| Desogestrel | The therapeutic efficacy of Desogestrel can be decreased when used in combination with Alitretinoin. |
| Megestrol acetate | The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Alitretinoin. |
| Levonorgestrel | The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Alitretinoin. |
| Medroxyprogesterone acetate | The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Alitretinoin. |
| Norethisterone | The therapeutic efficacy of Norethisterone can be decreased when used in combination with Alitretinoin. |
| Ethynodiol diacetate | The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Alitretinoin. |
| Norgestimate | The therapeutic efficacy of Norgestimate can be decreased when used in combination with Alitretinoin. |
| Drospirenone | The therapeutic efficacy of Drospirenone can be decreased when used in combination with Alitretinoin. |
| Cyproterone acetate | The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Alitretinoin. |
| Gestodene | The therapeutic efficacy of Gestodene can be decreased when used in combination with Alitretinoin. |
| Hydroxyprogesterone caproate | The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Alitretinoin. |
| Dienogest | The therapeutic efficacy of Dienogest can be decreased when used in combination with Alitretinoin. |
| Norethynodrel | The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Alitretinoin. |
| Norgestrel | The therapeutic efficacy of Norgestrel can be decreased when used in combination with Alitretinoin. |
| Gestrinone | The therapeutic efficacy of Gestrinone can be decreased when used in combination with Alitretinoin. |
| Lynestrenol | The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Alitretinoin. |
| Chlormadinone | The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Alitretinoin. |
| Norgestrienone | The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Alitretinoin. |
| Quingestanol | The therapeutic efficacy of Quingestanol can be decreased when used in combination with Alitretinoin. |
| Demegestone | The therapeutic efficacy of Demegestone can be decreased when used in combination with Alitretinoin. |
| Nomegestrol acetate | The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Alitretinoin. |
| Vitamin A | The risk or severity of adverse effects can be increased when Vitamin A is combined with Alitretinoin. |
| Valproic acid | Valproic acid may increase the Pseudotumor Cerebri activities of Alitretinoin. |
| Doxycycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Doxycycline. |
| Clomocycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Clomocycline. |
| Tigecycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Tigecycline. |
| Oxytetracycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Oxytetracycline. |
| Demeclocycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Demeclocycline. |
| Tetracycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Tetracycline. |
| Metacycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Metacycline. |
| Minocycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Minocycline. |
| Rolitetracycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Rolitetracycline. |
| Sarecycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Sarecycline. |
| Eravacycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Eravacycline. |
| Omadacycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Omadacycline. |
| Penimepicycline | The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Penimepicycline. |
| Lymecycline | The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Alitretinoin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alitretinoin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alitretinoin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alitretinoin. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alitretinoin. |
| Palovarotene | The risk or severity of adverse effects can be increased when Alitretinoin is combined with Palovarotene. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Quinisocaine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Alitretinoin is combined with Etrasimod. |